Literature DB >> 25667486

Left ventricular systolic dysfunction in metastatic breast cancer patients: a Polish multicenter registry.

Sebastian Szmit1, Joanna Streb2, Wioletta Starzec3, Dorota Zuziak4, Mariusz Kwiatkowski3, Bogumiła Czartoryska-Arłukowicz5, Dariusz Iżycki6, Anna Śmiałowska-Janiszewska7, Jerzy Hanslik8, Agnieszka Bryjak7, Małgorzata Talerczyk9, Jan Maciej Zaucha10.   

Abstract

BACKGROUND: The knowledge of the epidemiology of left ventricular systolic dysfunction (LVSD) in relationship with cardiovascular diseases, their risk factors and history of previous anticancer therapy may lead to development of safer and more effective therapeutic strategies in patients with breast cancer (BC). PATIENTS AND METHODS: Oncologists from various Polish Centers reported 299 new cases of metastatic BC requiring chemotherapy. All registered previous cardiological and oncological therapies should be conducted in accordance with the mandatory guidelines.
RESULTS: Twelve new cases (4%) of LVSD were recognized in echocardiography before current chemotherapy. Multivariate logistic regression analysis revealed a significant association of LVSD with hypercholesterolemia (odds ratio (OR)=8.83; 95% confidence interval (CI)=1.44-54.16; p<0.02), prior myocardial infarction (OR=26.81; 95%CI=2.26-318.43; p<0.01), prior antracycline-based therapy either neoadjuvant (OR=13.21; 95%CI=2.18-80.12, p=0.005) or adjuvant (OR=6.94; 95%CI=1.003-47.985, p<0.05).
CONCLUSION: LVSD in metastatic BC reflects common negative effects of hypercholesterolemia, coronary events and neoadjuvant/adjuvant chemotherapy with anthracyclines. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Anthracyclines; chemotherapy; left ventricular systolic dysfunction; metastatic breast cancer; risk factors

Mesh:

Year:  2015        PMID: 25667486

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Echocardiographic assessment of myocardial infarction: comparison of a rat model in two strains.

Authors:  R Esmaeili; A Sadeghpour; A Darbandi-Azar; K Majidzadeh-A; A Vajhi; M Sadeghizadeh
Journal:  Iran J Vet Res       Date:  2017       Impact factor: 1.376

2.  Cardiovascular risk factors among cancer patients qualified for systemic treatment. Analysis of a cardiovascular disease-free cohort from the Polish multicentre study ONCOECHO.

Authors:  Marta Nowakowska; Edyta Płońska-Gościniak; Andrzej Szyszka; Łukasz Chrzanowski; Magdalena Krakowska; Piotr Potemski; Katarzyna Mizia-Stec; Zbigniew Gąsior; Artur Bodys; Maciej Siński; Adrianna Gościńska-Szmagała; Piotr Gościniak; Monika Różewicz; Beata Zaborska; Wojciech Braksator; Dariusz Kosior; Jarosław D Kasprzak
Journal:  Arch Med Sci       Date:  2020-11-02       Impact factor: 3.318

3.  Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.

Authors:  Sebastian Szmit; Aleksandra Grela-Wojewoda; Małgorzata Talerczyk; Joanna Kufel-Grabowska; Joanna Streb; Jolanta Smok-Kalwat; Dariusz Iżycki; Ewa Chmielowska; Michał Wilk; Barbara Sosnowska-Pasiarska
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.